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Abstract
Background: Delirium is a frequent disorder in intensive care unit (ICU) patients with serious consequences.
Therefore, preventive treatment for delirium may be beneficial. Worldwide, haloperidol is the first choice for
pharmacological treatment of delirious patients. In daily clinical practice, a lower dose is sometimes used as
prophylaxis. Some studies have shown the beneficial effects of prophylactic haloperidol on delirium incidence as
well as on mortality, but evidence for effectiveness in ICU patients is limited. The primary objective of our study is
to determine the effect of haloperidol prophylaxis on 28-day survival. Secondary objectives include the incidence of
delirium and delirium-related outcome and the side effects of haloperidol prophylaxis.
Methods: This will be a multicenter three-armed randomized, double-blind, placebo-controlled, prophylactic
intervention study in critically ill patients. We will include consecutive non-neurological ICU patients, aged ≥18 years
with an expected ICU length of stay >1 day. To be able to demonstrate a 15% increase in 28-day survival time with
a power of 80% and alpha of 0.05 in both intervention groups, a total of 2,145 patients will be randomized; 715 in
each group. The anticipated mortality rate in the placebo group is 12%. The intervention groups will receive
prophylactic treatment with intravenous haloperidol 1 mg/q8h or 2 mg/q8h, and patients in the control group will
receive placebo (sodium chloride 0.9%), both for a maximum period of 28-days. In patients who develop delirium,
study medication will be stopped and patients will subsequently receive open label treatment with a higher
(therapeutic) dose of haloperidol. We will use descriptive summary statistics as well as Cox proportional hazard
regression analyses, adjusted for covariates.
Discussion: This will be the first large-scale multicenter randomized controlled prevention study with haloperidol in
ICU patients with a high risk of delirium, adequately powered to demonstrate an effect on 28-day survival.
Trial registration: Clinicaltrials.gov: NCT01785290.
EudraCT number: 2012-004012-66.
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Background
Delirium is a neuropsychiatric disorder characterized by
an acute onset of confusion, inattention, and a change in
level of consciousness that tends to fluctuate during the
day [1,2]. The incidence of delirium in intensive care
unit (ICU) patients is high [3-6], approximately 30–50%.
Further, its occurrence is associated with detrimental
outcome, including prolonged duration of mechanical
ventilation, increased ICU and hospital length of stay
(LOS) [4-6], unplanned removal of tubes and catheters
[6], increased mortality [6-8], and long-term cognitive
disturbances [9,10]. Therefore, a strategy that can prevent
delirium in high-risk patients may also decrease short-term
(i.e., 28-day) mortality.
The first step in the management of delirium is to treat
the underlying disease. If delirium does not subside,
haloperidol is the most frequently used pharmacologic
treatment of delirium. However, this drug may also be
used to prevent delirium. In non-ICU patients, beneficial
effects have been reported of prophylactic haloperidol
in older and surgical patients [11,12]. For critically ill
patients, data concerning prevention with anti-psychotic
drugs are scarce and inconsistent [13-15]. In one retro-
spective cohort study, ICU patients who received haloperi-
dol were found to have a lower mortality rate compared to
ICU patients that did not receive haloperidol [16]. Only
one prospective, randomized trial in critically ill patients
is available, showing that haloperidol prophylaxis in
non-cardiac surgical ICU patients had beneficial effects
on delirium incidence and the number of delirium free-
days [17]. However, only a very low dose, for 12 h infusion
of haloperidol was administered and many of the patients
were in the ICU for less than 24 h [17]. Thus, there are
no large, definitive trials that have studied the effect of
haloperidol prophylaxis in ICU patients.
Recently, a model was developed and validated to pre-
dict delirium in ICU patients [18]. With this model, the
effectiveness of preventive strategies can be compared in
different groups that differ in a priori risk of delirium.
This delirium prediction model was used to identify high-
risk ICU patients (i.e., a priori risk of delirium >50%). Com-
pared to a historical control group, prophylactic low-dose
haloperidol was associated with better delirium related
outcomes. In this high-risk group (>50%) of critically ill
patients, incidence of delirium was significantly lower in
the preventive treatment group (65%), compared to the
control group (75%). Furthermore, haloperidol prophylaxis
was associated with a hazard rate of 0.8 for 28-day mortality
[19]. However, because of the pre-/post-implementation
design of this trial, other factors that may have changed
between the study periods may have influenced these find-
ings. Nevertheless, the results suggest that prevention of
delirium might be beneficial in critically ill patients. Since
no relevant side effects associated with the administration
of a low dosage of haloperidol were reported in the
prophylactic studies [11,12,17,19], it is conceivable that a
higher dose of haloperidol may exert more pronounced
beneficial effects. Furthermore, the optimal dosage of halo-
peridol in critically ill patients, as well as the occupancy
levels of dopamine-2 receptors and sigma-1 receptors when
administering haloperidol, remain unknown. Therefore, in
the present study proposal the effects of two dosages of
haloperidol versus placebo will be determined.
Given the fact that the development of delirium can
be predicted only 24 h after ICU admission, and the
clear relation between time to treatment with haloperidol
and the duration of delirium [19], initiation of prophylaxis
as early as possible is warranted. Based on our historical
data, the median predicted risk of delirium is approxi-
mately 35% in patients with an expected stay on the
ICU of over one day; this is considered a high risk for
delirium development. A clinical estimation of an ICU
LOS >1 day is possible within the first few hours after ICU
admission. Previous studies that included patients using
similar criterion of an expected ICU LOS were found feas-
ible [20,21]. Therefore, the clinical estimation by the attend-
ing ICU-physician of an ICU LOS >1 day will be used as an
inclusion criterion for this study, in which the prediction to
develop delirium (using the PRE-DELIRIC model [18]) will
be used to facilitate post-hoc analyses to investigate which
patients benefit most from prophylactic therapy. By using
the PRE-DELIRIC score as an a priori determined post-hoc
analysis, we will learn if the putative beneficial effect of
haloperidol is related to the risk to develop delirium, or
comparable in all patients, independent of the baseline risk
to develop delirium. In addition, it will facilitate the deter-
mination of a cut-off level for the PRE-DELIRIC score.
Potential side effects of haloperidol include extra
pyramidal symptoms, drowsiness, agitation, and ventricular
arrhythmias. The latter are extremely rare (only case-reports
are published [22-25]) and dose dependent. With the
haloperidol dosage that will be used in the present study
(3x1 mg or 3x2 mg intravenously daily), no relevant side
effects are expected, regardless of underlying condition,
organ dysfunction, and concomitant medication. Never-
theless, and given the preventive nature of this study,
extra attention is being paid to the recognition of pos-
sible side effects of haloperidol that could mitigate its
potential beneficial effects. Importantly, in three recent
prophylactic haloperidol studies [11,17,19] no relevant
side effects, and in particular no ventricular arrhythmias,
were reported using similar low dosages of haloperidol
as described in the present protocol. Regarding the
choice of haloperidol dosage, this was based on the pre-
vious study in which no relevant side effects were found
when using a prophylactic dose of 3x1 mg in delirium
high-risk ICU patients, and resulted in a significant
decrease of delirium incidence [19]. However, in this
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high-risk group (mean delirium risk of 75%) the inci-
dence was still 65%, suggesting that a higher dosage of
haloperidol might decrease the incidence of delirium
to a greater extent. For this reason, and taking into account
the non-relevant side effects, we choose to add a third arm
using a higher dose of 3x2 mg haloperidol.
The aim of this study is firstly to determine the effect
of two different low dosages of prophylactic haloperidol
on 28-day mortality as well as the incidence of delirium
and other delirium related outcome measures and quality
of life, compared with placebo, in ICU patients with an ex-
pected ICU stay of >1 day. Secondly, to relate the potential
beneficial effects of haloperidol to the a priori risk of devel-
oping delirium, using the PRE-DELIRIC model [18]. Lastly,
to evaluate possible side effects of prophylactic haloperidol.
Methods
This study protocol is in accordance with the CONSORT
guidelines concerning randomized controlled trials [26].
Design and setting
A prospective, multicenter, three-armed, permuted block-
randomized, double-blind, placebo-controlled, prophylactic
intervention study will be conducted in critically ill patients
with a high risk of delirium development. All participating
sites are members of the Dutch Intensive Care Unit
Delirium Consortium facilitating the collaboration related
to delirium research in the ICU. In all centers, patients
are screened for delirium using the validated Dutch
translation of the Confusion Assessment Method-Intensive
Care Unit (CAM-ICU) [27-29] by well-trained ICU nurses,
at least two times a day and more often if indicated (during
periods of fluctuating symptoms or levels of sedation).
Before initiation of the study, ICU nurses will receive
additional information concerning the CAM-ICU on
top of their in-house CAM-ICU training. Furthermore,
during the study, inter-rater reliability measurements
of the CAM-ICU and the Richmond Agitation Sedation
Score (RASS), as part of the CAM-ICU, will be performed
in order to check the quality of the assessments, and if
necessary, additional training will be provided.
The study will start after training of all centers including
an initiation visit.
Study population
Inclusion criteria
All consecutive critically ill patients admitted to the ICU
aged ≥18 years at the time of ICU admission and with
an expected length of ICU stay of over one day will be
included as informed consent is obtained.
Data from patients that are included in the study, but
who do not receive any study drug and are discharged
from the ICU within 24 h will be discarded from further
analysis. Patients who received at least one dose will
remain in the study and patients in whom study medi-
cation had to be halved or stopped, e.g., because of
prolonged QTc time or other side effects, will remain
allocated to their study group and analyzed on an
intention-to-treat basis.
Exclusion criteria
The following will be considered exclusion criteria: no
informed consent obtained; history of epilepsy, Parkinson’s
disease, hypokinetic rigid syndrome, dementia or alcohol
withdrawal syndrome; patients admitted to the ICU for
any other neurological disease (including post-cardio-
pulmonary resuscitation patients, and patients admitted
with coma due to overdose); patients treated with anti-
psychotic therapy over the last 30 days prior to ICU
admission; prolonged QTc-time (>500 msec) or history
of clinically relevant ventricular arrhythmia in last 12
months; pregnancy/breast feeding; documented delirium
prior to ICU admission; reasons that impair delirium
assessment with the CAM-ICU (serious auditory or visual
disorders, unable to understand Dutch or English; severely
mentally disabled; serious receptive aphasia); ICU-stay less
than one day; moribund and not expected to survive two
days; known allergy to haloperidol.
Objectives
Definitions of variables in objectives are reported in
Table 1.
Primary objective
To determine the effect of prophylactic haloperidol use
on 28-days survival.
Secondary objectives
There are seven secondary objectives:
1. To determine the effect of prophylactic haloperidol
use on 90-day survival; survival analysis stratifying
for delirium incidence will be performed.
2. To determine the effect of prophylactic haloperidol
use on the incidence of delirium.
3. To determine the effect of prophylactic haloperidol
use on the number of delirium- and coma-free days
in a period of 28 days.
4. To determine the effect of prophylactic haloperidol
use on delirium related outcomes: time to successful
extubation, incidence of re-intubation, incidence of
ICU readmission, and incidence of unplanned re-
moval of tubes and catheters.
5. To evaluate the incidence and severity of side effects
of haloperidol prophylaxis.
6. To determine the effect of preventive haloperidol
use on quality of life 1 and 6 months following ICU
admission compared with a baseline measurement at
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ICU admission using the Short Form-12 (SF-12)
questionnaire.
7. A priori defined post-hoc analyses:
a. To determine the preventive effectiveness of
haloperidol in different patient groups based on
the a priori risk to develop delirium: patients with
a predicted risk up to 50%, 50–70%, 70–90%,
above 90% will be evaluated.
b. To determine the preventive effectiveness of
haloperidol in different patient groups: medical/
surgical/trauma patients, per acute physiology
and chronic health evaluation-II (APACHE-II)
score (<20, 20–25, >25)
c. Effectiveness of prophylaxis when delirium is
diagnosed based on 1, 2, or more days with
positive CAM-ICU scoring.
Randomization
Block randomization will be applied by the pharmacist.
The randomization numbers are coupled with the Clinical
Report Form (CRF) number and the number of study
medication box. Boxes are numbered and consist of 12
ampoules of study drug. If necessary, when a patient is
admitted to the ICU for more than 4 days and is not
delirious, a new box will be assigned to this patient con-
sisting of the same study regime as the previous box. All
study medication will be manufactured by the Department
of Clinical Pharmacy of the Radboud University Nijmegen
Medical Centre, which holds a Good Manufacturing
Practice certificate. Ampoules of study medication consist of
1 mg/mL or 2 mg/mL haloperidol or 1 mL sodium chloride
0.9% solution, all with a total volume of 1 mL. The
randomization code is kept by the pharmacist and will
be broken only if necessary for safety reasons. Only
the pharmacist of the Radboud University Nijmegen
Medical Centre is unblinded for this study.
Intervention and control group
This study involves a comparison of prophylactic haloperi-
dol in a dosage of 1 mg (intervention group 1) or 2 mg
Table 1 Definition of study objectives
Objective Definition
Survival days in 28 days Number of days that patients survive in 28 days. All patients will be classified as either ‘alive at study
day 28’ or, if dead, ‘dead at study day 28’ on an intention-to-treat basis.
Delirium diagnosis Patients are diagnosed as delirious when they have at least one positive CAM-ICU screening during
their complete ICU stay. Patients who were not delirious during their ICU-stay are considered as
non-delirious patients.
Delirium-and-coma-free days in 28 days Number of days that the patient is alive and not delirious and not in coma over 28 days starting from
the day of inclusion. A delirium-and-coma-free day is defined as a negative CAM-ICU screening with a
Richmond Agitation Sedation Score (RASS) greater than (more alert than) -3/-4/-5 during a day. In case
a delirious patient is discharged to the ward, a delirium-free day is defined as a delirium observation
scale score [30] of less than 3 during a complete day.
Duration of mechanical ventilation Time in days that the patient is on the mechanical ventilator. If the patient is ventilated mechanically
several times during one ICU admission, then the ventilator times are added. Both invasive and
non-invasive ventilation will be registered. Ventilator-free days (in 28 days) will be calculated.
Incidence of re-intubation Patients who need to be intubated within 28 days from randomization, following a previous extubation,
irrespective of the reason for re-intubation, are counted as incident case for re-intubation.
Incidence of ICU readmission Patients who need to be readmitted to the ICU during within 28 days from randomization, irrespective
of the reason for readmission, are counted as incident cases for ICU readmission.
Side effects Drowsiness, agitation, QTc-time prolongation (using 12-leads ECG or monitor strip with Bazett’s formula)
and development of extra pyramidal symptoms such as tandem gait, dystonia, tremor, myoclonus, tics,
rigidity, akathisia [31], determined daily by physical examination by the intensivist.
Serious adverse event Any untoward medical occurrence or effect at any dose that results in one of the following outcomes
and is not classified as a clinical outcome of delirium or the underlying disease using the description above:
- death that is not related to the underlying disease or sequel of the underlying disease, or death
that is considered by the investigator to be related to study drug
- prolonged inpatient hospitalization or re-hospitalization
- a life-threatening experience (that is, immediate risk of dying)
- persistent or significant disability/incapacity
- congenital anomaly/birth defect
- considered significant by the investigator for any other reason
Sudden unexpected serious adverse reactions Unexpected adverse reactions are adverse reactions, of which the nature, or severity, is not consistent
with the applicable product information. Adverse reactions are all untoward and unintended responses
to an investigational product related to any dose administered.
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(intervention group 2) administered as a bolus intraven-
ously three times a day compared with placebo of 0.9%
sodium chloride (control group) administered intravenously
three times a day in a double-blind fashion. All ampoules
and drug boxes have an identical appearance.
To decrease the likelihood of encountering side effects in
specific cohorts, the dose of the study drug will be halved
in patients aged ≥80 years, weighing ≤50 kg, suffering from
liver failure (indicated by serum bilirubin level >50 μmol/L)
present at time of inclusion or during the study. Patients
with an adjusted dose remain allocated to their original
group (intention-to-treat).
Patients with an adjusted dose remain allocated to their
original group (intention to treat).
End of study medication
Prophylactic treatment with haloperidol will be continued
until day 28, or discharge from the ICU (whatever comes
first), or until delirium occurs. In the latter case, patients will
be subsequently treated according to the delirium treatment
protocol (with higher dosage of open label haloperidol).
In case delirium occurs, the patient’s study medication
(prophylaxis treatment) will be stopped and the patient will
be treated with open label haloperidol according to the
delirium treatment protocol described below. Analysis
will be on intention-to-treat basis. Study medication will
not be restarted once delirium subsides, therapeutic
haloperidol is stopped, or when a patient is re-admitted
to the ICU within 28 days.
Delirium treatment
Patients with delirium (defined as a positive CAM-ICU test)
will be treated with 2 mg haloperidol intravenously
three times daily. Patients suffering from hypoactive
delirium (only RASS scores between 0 and −3) and patients
aged ≥80 years, weighing ≤50 kg, or with liver failure, will
be treated with a lower dosage of 3x1 mg intravenously.
Dosage can be increased up to a maximum of 3x5 mg
in case of serious agitation or anxiety due to delirium.
Additionally, midazolam, clonidine, propofol, or dexmedeto-
midine can be used as an escape therapy in case of serious
agitation with insufficient efficacy of haloperidol according
to usual patient care.
In patients treated for more than three days, the dosage
will be halved when delirium subsides. When delirium
does not reoccur the following day (CAM-ICU remains
negative), the dosage will be halved again and then stopped
the third day when the patient remains non-delirious. In
case delirium occurs again during the reducing phase,
the original dose will be restarted.
Data collection
All data will be collected electronically in an electronic
CRF (E-CRF). The E-CRF is a secured website where
the participating hospitals must login using a unique
password. Participating hospitals will only have access
to their own data.
Demographic variables will be collected from all patients,
including age, gender, PRE-DELIRIC score, APACHE-II
score, and diagnosis group. Furthermore, outcome related
variables will be collected (Table 2) as well as variables
that may influence the delirium outcome, i.e., dexme-
detomidine [32] and early mobilization [33]. Concerning
the study medication, we will collect data on the amount
of study drug administered as well as open-label halo-
peridol and other anti-delirium drugs administered in
case delirium occurs.
Safety monitoring and safety issues
A Data Safety Monitor Board (DSMB) is established for
this study to perform ongoing safety surveillance and to
perform interim analyses on the safety data. This is an
independent committee composed of two physicians/
researchers (a psychiatrist and an anesthetist) and a
statistician. The DSMB will perform all interim analyses.
To assess side effects of haloperidol and to determine
superiority of the intervention or placebo the DSMB
will be unblinded for this study, while all researchers
remain blinded. Furthermore, the study will be monitored
by an independent researcher who will monitor the trial
master file, and perform random checks of informed
consent forms, drug accountability lists, and source data
of primary and secondary outcome measures.
Concerning safety issues, during a patient’s treatment
with the study medication, known side effects of haloperidol
[34] are pro-actively collected with a special focus on
prolonged QTc-time, drowsiness, extrapyramidal symp-
toms, and agitation and sedation effects. All side effects
will be collected during patients’ treatment with the
study medication until 24 h after stopping the study
medication. In case of the occurrence of side effects,
physicians can reduce the dosage or stop the study
medication, depending on the severity of the occurred
side effect and at the discretion of the attending phys-
ician. Only for prolonged QTc-time, strict stopping
rules are applied, as described below. To detect side
effects of haloperidol, the protocol dictates that patients
are physically examined every day for known signs of
extrapyramidal symptoms (signs of Parkinsonism and/or
akathisia and/or dystonia). Furthermore, daily QTc-
time is calculated using a 12-lead ECG or a monitor
lead ECG. A QTc-time of over 500 msec combined with
an increase of over 10% of baseline QTc-time is defined
as prolonged QTc-time. In case of QTc-time prolonga-
tion, the study drug is temporarily stopped until QTc-
time is normalized. After normalization of QTc-time
(<500 msec) the study drug will be restarted. If QTc-time
becomes prolonged again, the study drug will be stopped
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definitively. The patient will remain allocated to the
original study group.
To determine long-term side effects, such as rigidity,
and quality of life, a recommended and validated quality
of life questionnaire, SF-12 [35], is taken at the time of
admission and is sent to the patients 1 and 6 months
after ICU admission.
The following adverse events will be collected: serious
adverse events; non-serious adverse events that are
considered by the investigator to be possibly related to
the study drug (e.g., prolonged QTc-time, drowsiness,
extrapyramidal symptoms, agitation and sedation effects);
adverse events that lead to permanent discontinuation
of the study drug administration. A serious adverse
event is any untoward medical occurrence or effect at
any dose that results in one of the following outcomes
and is not classified as a clinical outcome of delirium
or the underlying disease using the description: death
that is not related to the underlying disease or sequel
of the underlying disease, or death that is considered by
the investigator to be related to the study drug; prolonged
inpatient hospitalization or re-hospitalization; a life-
threatening experience (that is, immediate risk of dying);
persistent or significant disability/incapacity; considered
significant by the investigator for any other reason.
Sample size calculation and statistics
Sample size calculation is based on the difference in
survival from our previous prophylactic haloperidol
study [19]. In this study, the median survival time in
the control group was 18 days. If the true hazard ratio
of control patients relative to intervention patients is
0.85, taking into account an accrual time of 90 days with
28 days of follow-up, we will need to study 647 patients
per intervention group and 647 control patients to be able
to reject the null hypothesis that the experimental and
control survival curves are equal with probability (power)
0.80. The Type I error probability associated with this
null hypothesis test is 0.05. Taking into account a dropout
percentage of 10%, we will include 715 patients per group
(Figure 1). A fixed sequence procedure will be followed.
First, the highest dosage of prophylactic haloperidol will
be compared with placebo using alpha 0.05 (two-sided).
Only if H0 is rejected, subsequently the lower dosage of
prophylactic haloperidol will be compared with placebo.
Cox regression analysis will be used to test differences
on 28-day survival in the intervention group compared
with the placebo group.
A safety, futility, and superiority interim analysis will
be performed by the DSMB after 175, 350, 500 (safety
and futility) and 1,000 (safety and superiority) patients are
included. Differences in serious adverse events between
intervention and placebo are used for safety analyses and
the primary endpoint 28-day survival is used to determine
futility or superiority of intervention or placebo.
After the inclusion of 1,000 patients, superiority will
be tested. A proven superiority (P < 0.003, two-sided) of any
dose of haloperidol over placebo or a proven superiority
(P < 0.003, two-sided) of placebo over haloperidol deter-
mined during the interim analysis will result in an alpha of
0.049 (two-sided) for the final analysis. This alpha distribu-
tion was calculated by an independent statistician according
to the method of Lan-DeMets cumulative alpha spending
function of O’Brien-Fleming alpha spending [36].
Data will be analyzed according to the intention-to-
treat principle. For the descriptive statistics, continuous
variables will be given as mean with standard deviation
or median and inter quartile ranges, depending on their
distribution. Normally distributed variables will be tested
using Student’s t-test for comparison and Mann-Whitney
U-tests for non-normally distributed variables. Categorical
(and binary) variables will be presented as numbers and
percentages and will be analyzed using the χ2 test. Survival
analyses with Kaplan-Meier curves will be used as graphical
representation. Cox proportional hazard regression analyses
will be used to estimate the hazard ratio for survival
with the use of haloperidol versus placebo. Furthermore,
we will perform adjusted analyses for relevant covariates
Table 2 Primary, secondary endpoints and posthoc analyses
Primary endpoint Secondary endpoints Post-hoc analyses
28-day mortality 90-day mortality
Delirium incidence
Effectiveness in groups of predicted risk up to 50%,
50–70%, 70–90%, above 90% will be evaluated
Number of delirium and coma free-days in 28 days Effectiveness in diagnosis groups: medical, surgical
and trauma patients
Duration of mechanical ventilation Effectiveness per APACHE-II score: <20, 20–25, >25
Incidence of unintended tube or catheter removal Effectiveness in groups with 1, 2, or more positive
CAM-ICU scores
Incidence of ICU re-admission
Quality of life measured at time of ICU admission,
after 1 and 6 months using SF-12
Incidence and severity of side effects of prophylactic
haloperidol (all patients)
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(including delirium, APACHE-II score, age, sex, sepsis, and
other differences between the three study groups irrespect-
ive of the possible imbalance between the three groups). For
this covariate analysis, univariate logistic regression ana-
lysis will be performed first in order to test the strength
of the relationship. Subsequently, variables significantly
associated with the dependent variable will be included
in the covariate analyses.
Furthermore, subgroup analysis will be performed by
direct comparisons of a priori specified subgroups, i.e.,
predicted risk group, admission type group, and APACHE-II
group, in order to determine effectiveness of prophylactic
haloperidol treatment in these subgroups on 28-day survival.
All statistical tests are two-sided and statistical significance
is defined as a P value < 0.05. All data will be analyzed using
SPSS version 20.01 (SPSS, Chicago, IL, USA).
Ethics
The study will be conducted according to the principles
of the Declaration of Helsinki (version 2008) and in
accordance with the Medical Research Involving Human
Subjects Act.
There are indications that early treatment of delirium is
more effective than delayed treatment [37], but this needs
to be confirmed in other studies. Since it is recognized
that the onset of delirium occurs, on average, on day 2
after ICU admission, early preventive treatment is likely
to be more effective. In the short-term, low dose halo-
peridol has no known relevant side effects, therefore
randomization and administration of study medication
will be started immediately following identification of a
high-risk patient. When an informed consent procedure re-
sults in a delay of randomization, a deferred consent proced-
ure may be followed. The informed consent procedure will
be started as soon as possible, but always within 24 h follow-
ing ICU admission. If no deferred informed consent can be
obtained within 24 h, the patient will be excluded from the
study and study drug administration will be stopped.
The medical ethical committee of Arnhem-Nijmegen
(CMO) approved this study including this deferred consent
procedure (CMO-number 2012/424). This trial is registered
on clinicaltrials.gov: NCT01785290.
Discussion and trial status
This is the first large-scale multicenter randomized-
controlled prevention study with haloperidol in ICU
patients with an increased risk to develop delirium. The
study design and protocol was finalized in 2012 and the
protocol passed the medical ethical committee on February
2013. Prior to the start of the study, all centers will be
visited to inform all involved researchers and a second
meeting will take place as an initiation visit. Furthermore,
a meeting with the DSMB and the monitor will be
scheduled prior to the conduction of the study.
Figure 1 CONSORT flowchart of patient enrollment.
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Results of our study will be of importance for critically
ill patients and permits us to draw conclusions on the
effectiveness of haloperidol prophylaxis in reducing 28-day
mortality, preventing delirium, and improving delirium-
related outcome. Furthermore, it will provide information
regarding the delirium-risk category in which the PRE-
DELIRIC model prophylaxis is most effective. Positive
effects of haloperidol prophylaxis on delirium outcome
will result in the alteration of daily practice for critic-
ally ill patients and would therefore have major impli-
cations. However, if there is no effect of haloperidol
prophylaxis, other possibilities of delirium prevention,
such as nursing interventions, need to be studied. In
addition, the effectiveness of nursing interventions focus-
ing on delirium prevention can be studied in conjunction
with haloperidol prophylaxis.
Trial status
Preparations of the study are nearing completion. We
expect that the study will start mid-2013.
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